P586: IADADEMSTAT COMBINATION WITH AZACITIDINE SHOWS ENCOURAGING SAFETY AND EFFICACY DATA IN ELDERLY AND UNFIT AML PATIENTS

P586: IADADEMSTAT COMBINATION WITH AZACITIDINE SHOWS ENCOURAGING SAFETY AND EFFICACY DATA IN ELDERLY AND UNFIT AML PATIENTS

Bibliographic Details
Main Authors:	O. Salamero, T. Somervaille, A. Molero, E. Acuña-Cruz, J. A. Perez-Simon, R. Coll, M. Arnan Sangerman, B. Merchan, A. Perez, I. Cano, R. Rodriguez-Veiga, M. Arevalo, S. Gutierrez, C. Buesa, F. Bosch, P. Montesinos
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845232.86593.bf

Similar Items

PB1850: A DOSE FINDING AND EXPANSION OPEN LABEL, MULTICENTER STUDY OF IADADEMSTAT AND GILTERITINIB IN PATIENTS WITH RELAPSE/REFRACTORY ACUTE MYELOID LEUKEMIA WITH MUTATED FLT3: THE FRIDA STUDY
by: A. Fathi, et al.
Published: (2022-06-01)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
by: N. Daver, et al.
Published: (2022-06-01)

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
by: Deepak Kumar Shukla, et al.
Published: (2021-01-01)

PB1905: REAL-WORLD EXPERIENCE OF LOW-DOSE VENETOCLAX WITH AZACITIDINE FOR UNFIT AML PATIENTS(≥60Y) WITH LOW LEUKOCYTE COUNT
by: Wenjian Wei, et al.
Published: (2023-08-01)

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
by: Jorge Labrador, et al.
Published: (2022-05-01)

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
by: Juan Miguel Bergua Burgues, et al.
Published: (2023-08-01)

Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia
by: Tzu-Ting Chen, et al.
Published: (2024-03-01)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Xiao Han, et al.
Published: (2023-08-01)

P534: AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS
by: S. Garciaz, et al.
Published: (2022-06-01)

Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy
by: David Sanford, et al.
Published: (2022-09-01)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
by: Esther Natalie Oliva, et al.
Published: (2023-04-01)

P582: AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS
by: Hong Pan, et al.
Published: (2023-08-01)

Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
by: António Almeida, et al.
Published: (2017-01-01)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
by: Musa Yilmaz, et al.
Published: (2022-05-01)

P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-001 TRIAL OF ORAL AZACITIDINE
by: A. H. Wei, et al.
Published: (2022-06-01)

BCL-2 inhibitor and conventional chemotherapy combinations for acute myeloid leukemia: shifting from the unfit to the fit patient with AML
by: Ossenkoppele, G, et al.
Published: (2020)

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML
by: Chen X, et al.
Published: (2023-06-01)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
by: Hua Jin, et al.
Published: (2023-04-01)

P412: LOW EXPOSURE, EXTENDED DOSING MIMICKING CLINICAL EXPOSURES OF ORAL AZACITIDINE SYNERGIZES WITH VENETOCLAX IN PRECLINICAL AML MODELS
by: D. Jeyaraju, et al.
Published: (2022-06-01)

Authors' List [pp. 573-586]
by: Hystrix Editor
Published: (2008-05-01)

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
by: Michael Loschi, et al.
Published: (2021-05-01)

Time-dependent treatment effects of metronomic chemotherapy in unfit AML patients: a secondary analysis of a randomised controlled trial
by: Phichayut Phinyo, et al.
Published: (2021-01-01)

Azacitidine prolongs overall survival in older patients with Acute Myeloid Leukemia (AML) with poor prognostic karyotypes
by: Doehner, H, et al.
Published: (2017)

Unfit for the Future by Laura Crompton
by: Laura Crompton
Published: (2014-05-01)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
by: Marina Konopleva, et al.
Published: (2023-08-01)

P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1)
by: E. Stein, et al.
Published: (2022-06-01)

L38S F586 (203-204)
by: Malaysia. Direktorat Pemetaan Negara

Causes of eye removal: Analysis of 586 eyes
by: Knežević Miroslav, et al.
Published: (2013-01-01)

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
by: DiNardo, CD, et al.
Published: (2021)

Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy
by: Guanghao Liang, et al.
Published: (2023-08-01)

Real-world treatments and clinical outcomes in unfit AML patients receiving first-line treatment or best supportive care in Italy (CURRENT study)
by: Maria Paola Martelli, et al.
Published: (2024-01-01)

HOW TO TREAT UNFIT AND FRAIL PATIENTS
by: Gordon Cook
Published: (2022-04-01)

The Unfitness of Traditional Military Thinking in Cyber
by: Jan Kallberg, et al.
Published: (2017-01-01)

P563: A RANDOMIZED, DOUBLE-BLIND, 2-ARM, MULTICENTER, PH3 STUDY OF VENETOCLAX & ORAL AZACITIDINE VS. ORAL AZACITIDINE AS MAINTENANCE THERAPY FOR PTS WITH AML IN FIRST REMISSION AFTER INTENSIVE CHEMOTHERAPHY
by: V. Ivanov, et al.
Published: (2022-06-01)

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
by: Goodyear, O, et al.
Published: (2012)

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, C, et al.
Published: (2022)

P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS
by: S. Venugopal, et al.
Published: (2022-06-01)

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
by: Lisa Pleyer, et al.
Published: (2017-02-01)

P517: PROSPECTIVE MULTICENTRIC STUDY ON INFECTIOUS COMPLICATIONS AND CLINICAL OUTCOME IN 230 UNFIT AML PATIENTS TREATED IN FIRST-LINE WITH HYPOMETHYLATING AGENTS ALONE OR IN COMBINATION WITH VENETOCLAX.
by: A. Candoni, et al.
Published: (2022-06-01)

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA
by: H. Dohner, et al.
Published: (2022-06-01)